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Abstract
De novo variants in DDX3X account for 1–3% of unexplained intellectual dis-
ability (ID) cases and are amongst the most common causes of ID especially in
females. Forty-seven patients (44 females, 3 males) have been described. We
identified 31 additional individuals carrying 29 unique DDX3X variants, includ-
ing 30 postnatal individuals with complex clinical presentations of developmen-
tal delay or ID, and one fetus with abnormal ultrasound findings. Rare or novel
phenotypes observed include respiratory problems, congenital heart disease,
skeletal muscle mitochondrial DNA depletion, and late-onset neurologic
decline. Our findings expand the spectrum of DNA variants and phenotypes
associated with DDX3X disorders.
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Introduction
Intellectual disability (ID) affects 1–3% of the popula-
tion and is more prevalent in males versus females.1
Although over 100 genes on the X chromosome were
found to be associated with ID in males,2,3 relatively
less is known about X-linked ID genes in females.4
Whole-exome sequencing (WES) is finding de novo
variants in X-linked ID genes in females of all ages.5–8
However, limited information is available regarding
such cases. Some of the genes causing ID in females
are known to cause disease in males, including PHF6,9
NEXMIF,8 and USP9X, with the latter causing congen-
ital malformations not observed in affected males.10
Further evidence for gender-specific variant pathogenic-
ity comes from DDX3X located on Xp11.4, with
pathogenic de novo variants causing syndromic ID in
39 females; in the same study, three males inherited
DDX3X variants from apparently unaffected mothers.11
Differences in predicted variant severity or X-chromo-
some inactivation studies from blood DNA did not
explain the gender-specific disease expression. Five
additional females with DDX3X variants have been
described in the literature.12–14 These reports led us to
hypothesize that females with de novo variation in
DDX3X may show additional clinical phenotypes. We
report 31 individuals with DDX3X-related disorders,
and provide comprehensive clinical presentations for
13, including expanding the age range of molecular
diagnosis with the oldest reported individual and a
fetus. These data expand the number of DDX3X
pathogenic variants and their associated phenotypic
spectrum.
Methods
Variants in DDX3X were identified by WES, performed
according to previously described methods,5,6,13 either on
a clinical basis at Baylor Genetics (Females 1–24, Males
1–2, Fetus 1) or on a research basis by the Baylor Hop-
kins Center for Mendelian Genomics (BHCMG, Females
25–27) or through the Centre de Genetique Humaine,
Universite de Franche-Comte (Female 28). Deidentified
reporting of aggregated demographic and molecular data
for all clinically referred cases was approved by the Insti-
tutional Review Board at Baylor College of Medicine
(BCM). Additional, informed consent for publication of
clinical details was obtained for a subset of clinically
referred cases and all research-based cases according to
IRB-approved protocols: at Baylor College of Medicine
(Female 8, 14, 17, 23, 24, 26), through the Undiagnosed
Diseases Network (UDN) protocol (Female 13), and
through the BHCMG (Females 7, 19, 25, 27); and at Cen-
tre de Genetique Humaine, Universite de Franche-Comte
(Female 28). Females 7 and 19 were previously reported
in a study of research-based reanalysis of clinical WES
data.13 DDX3X variants were annotated using transcript
NM_001193416. Variant pathogenicity was determined
based on the ACMG guidelines15 and the internal guideli-
nes developed at Baylor Genetics (https://www.baylorgene
tics.com/variant-classification/). For the interpretation of
de novo variants, the PS2 evidence is used if rare and/or
private variants in the proband were detected in both par-
ents by WES (Trio WES) or Sanger sequencing (proband
only WES). Otherwise the PM6 evidence is used. 0.1–
1 lg total RNA from patient fibroblast cells was extracted
for library preparation with TruSeq Stranded mRNA kit
1278 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
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and was sequenced by Illumina NextSeq 550. Genes with
expression at the top/bottom 5% were used for pathway
enrichment analysis by Ingenuity Pathway Analysis (IPA,
QIAGEN Inc., https://www.qiagenbioinformatics.com/pro
ducts/ingenuity-pathway-analysis).
Results
Among 4839 (2152 females, 2687 males) patients referred
to the Baylor Genetics laboratory for clinical WES with
developmental delay (DD) and/or ID, 26 postnatal indi-
viduals (24 females, 2 males) were found to carry patho-
genic or likely pathogenic variants in DDX3X, and 1
female fetus was found to carry a de novo variant of
unknown significance in DDX3X. Through collaboration
with the BHCMG and Centre de Genetique Humaine,
Universite de Franche-Comte, an additional four unre-
lated female cases (Females 25–28) were identified. The
ages at molecular diagnosis of the postnatal individuals
ranged from 1 to 47 years (Table S1). Twenty-nine
unique variants were identified (26 novel and 3 reported
previously), including 13 missense, 6 frameshift, 3 splice
site, 4 nonsense, and 3 in-frame deletion/duplication
changes (Table 1 and Fig. 1A and B). In 29 individuals
with available parents (27 female, 1 male, 1 fetus), the
DDX3X variants were confirmed as de novo, supporting
the variant pathogenicity. Two de novo variants,
c.573_575del (p.I191del) and c.1805G>A (p.R602Q) are
mosaic in the proband, with allele fractions of 21% and
14%, respectively (Table 1). The most frequent clinical
presentations in the 28 females include DD and/or ID
(28/28), hypotonia (19/28), dysmorphic features (19/28),
structural brain abnormalities (18/20 who had brain MRI,
Fig. S1), movement disorders (17/28), visual impairments
(9/28), and microcephaly (7/28) (Table 2). The most
commonly observed dysmorphic facial features include a
high-arched palate (5/19), thin upper lip (5/19), large ears
(5/19), and long/smooth/large philtrum (4/19). Clinical
presentations that are not present in published studies
include respiratory problems (5/28): obstructive sleep
apnea, tachypnea, and chronic respiratory failure, as well
as congenital heart disease (5/7 who had
Figure 1. Location of DDX3X variants identified in this study, Female individuals (25, 26, 27) ascertained through the BHCMG, and muscle
biopsy results in Female 17 showing abnormal mitochondrial morphology. (A) Schematic view of the DDX3X exon–intron structure based on
NM_001193416. Blue boxes represent exons and yellow fields represent introns. Exon number is listed below each exon. cDNA change is listed
for each variant. (B) Schematic view of the DDX3X protein structure based on Snijders Blok et al.11 Amino acid change is listed for each variant.
(C) Pedigree and Sanger tracings demonstrate de novo inheritance in three unrelated female probands. (D) Female 25 demonstrated synophrys, a
broad nasal root with upturned nostrils, a long philtrum, and thin upper lip. Female 27 demonstrated cupped ears, a long philtrum, and a thin
upper lip. (E–G) Muscle biopsy results in Female 17 (E) Skeletal muscle cross-section showing mild variation in fiber size (H&E; magnification
9400). (F) Skeletal muscle cross-section showing few fibers with mild subsarcolemmal increase in oxidative activity [cytochrome oxidase (long
arrow) and NADH tetrazolium reductase (inset – arrow heads; magnifications 9400)]. (G) Electron microscopic images showing mild
subsarcolemmal mitochondrial proliferation (long arrow) with inset in the upper corner showing pleomorphic abnormally elongated and irregularly
shaped mitochondria (arrow heads). Variant color in (A) and (B): black, first reported in this study; purple, previously reported. The c.1304T>C
(p.L435P) variant from Fetus 1 was not listed in (A) and (B).
Table 2. Comparison of clinical presentations in this study and in the published cohort.
Clinical features Number of subjects in this study Percentage in this study Percentage in the published cohort
DD and/or ID 28/28 100% 100%
Hypotonia 19/28 68% 76%
Dysmorphic features 19/28 68% NA
Structural brain abnormalities 18/20 90% 81%
Movement disorders 17/28 61% 45%
Visual impairments 9/28 32% 34%
Microcephaly 7/28 25% 32%
Autism spectrum disorders
and other behavior problems*
6/28 21% 53%
Respiratory problems 5/28 18% NA
Congenital heart disease 5/7 71% NA
Skin abnormalities* 5/28 18% 37%
NA, not specified or reported in the published study.10
*In comparison to published data, autism spectrum disorder and other behavior problems and skin abnormalities are underrepresented in our
cohort: 6/28 versus 20/38 (P = 5.2 9 103) and 5/28 versus 14/38 (P = 4.6 9 102), respectively. One-tailed Z score test for two population pro-
portions is used.
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echocardiogram): atrial/ventricular septal defect, double
orifice mitral valve with small patent ductus arteriosus,
mild concentric left ventricular hypertrophy and bicuspid
aortic valve. In comparison to published data, autism
spectrum disorder and other behavior problems and skin
abnormalities are underrepresented in our cohort
(Table 2). For 13 subjects, we obtained additional
informed consent and provide detailed clinical descrip-
tions (Table S1), as well as clinical images for two sub-
jects (Fig. 1D).
In two subjects undergoing muscle biopsy, skeletal mus-
cle mitochondrial DNA content was reduced. The first
subject (Female 17) is a 6-year-old nondysmorphic girl
with a history of neonatal hypotonia, esophageal reflux,
and global developmental delay. A quadriceps muscle
biopsy demonstrated mild fiber type variation and abnor-
mal pleomorphic mitochondria on electron microscopy
(Fig. 1E–G). After correction for the reduced citrate syn-
thase activity, respiratory chain enzyme activity analysis
demonstrated reductions of multiple complexes, with rela-
tive sparing of complex II activity. Sequencing of mito-
chondrial DNA from the muscle sample did not detect any
known or likely pathogenic variants. Mitochondrial DNA
content in muscle was 39% of age-matched control mus-
cle. Clinical WES demonstrated a de novo heterozygous
c.453_454del (p.S152 fs) pathogenic variant in DDX3X,
with no other variants in known disease-associated genes
that explain the patient’s clinical presentations. The second
subject is a 47-year-old woman (Female 13) with history
of global developmental delay, intellectual disability, short
stature, dysmorphic features, microcephaly, and unilateral
renal agenesis. She learned to sit at two years of age and
walk at eight, and she only learned to say simple words. In
her early 40 sec, she regressed, becoming nonverbal and
unable to ambulate or to use her arms. She was found to
carry a de novo heterozygous c.1600C>T (p.R534C) patho-
genic variant in DDX3X (Table 1). The same variant was
also observed in Female 14 in our cohort, and a variant
involving the same codon (p.R534H) has been reported in
a patient with ID.11 A quadriceps muscle biopsy demon-
strated severe mitochondrial and lipid depletion, and
reduction in mitochondrial size similar to Female 17.
Mitochondrial DNA content in muscle was 26% of the
mean value for age- and tissue-matched controls. A reduc-
tion in all mitochondrial respiratory chain complex activi-
ties was observed. However, the reduction do not meet
diagnostic criteria after correction for the low citrate syn-
thase activity.
Discussion
Normal RNA metabolism requires the function of RNA
helicases (RH), and yet, the exact function of most
human RH remains unknown. There are six superfamilies
of RH known with more than 50 human members in
superfamily two that are characterized by a DExH and
DExD signature in their Walker B motifs, thus termed
DHX and DDX proteins. Genetic studies have begun to
address the role of altered RH function in human disease
(e.g., DHX37 and DHX30).16,17 DDX3X encodes a DEAD-
box RNA helicase important in transcription, splicing,
RNA transport, and translation.18,19 In a diagnostic labo-
ratory referral cohort of 4839 subjects with DD and/or
ID, we have identified 26 postnatal individuals (24
females, 2 males) with syndromic ID or DD carrying
pathogenic or likely pathogenic variants in DDX3X, and
one fetus with abnormal ultrasound findings carrying a de
novo variant of unknown significance in DDX3X; an addi-
tional four females were identified through research WES
at BHCMG. The overall frequency of pathogenic or likely
pathogenic DDX3X variations in our diagnostic labora-
tory referral cohort is 0.54% of the total (26/4839) and
1.12% of females (24/2152), similar to a previous report
(0.6% and 1.5% respectively),10 confirming mutations in
DDX3X are one of the most common genetic causes of
unexplained ID in females. In our diagnostic laboratory,
DDX3X ranks third among approximately 450 genes for
the occurrence of de novo variants, with ARID1B first (43
individuals) and ANKRD11 sec (29 individuals).
In addition to confirming and extending published
mutational data, our phenotypic analyses expand the
phenotypic spectrum associated with DDX3X variants in
females. For instance, we found respiratory problems
and congenital heart disease in 5/28 and 5/7 of our
subjects, phenotypes not previously described in the
original description of DDX3X related disorders,11
although observed in a subsequent report of two
females.12 We found no evidence for genotype–pheno-
type correlations between the mutations we identified
and age at onset or phenotypic severity. Previously
reported individuals ranged in ages from 1 to 33 years.
We report the phenotype of a 47-year-old woman
(Female 13) who had manifestations consistent with
DDX3X disorder and a clinical picture of previously
unreported late-onset neurologic decline. The decline is
unrelated to intercurrent illness, and her motor func-
tion is at least in part responsive to physical therapy.
Of note, other X-linked DD/ID loci, exemplified by
female FMR1 premutation [MIM: 300623] and MECP2
duplication carriers,20 are notable for late adult onset
neurological or neurocognitive phenotypes.
Two variants reported in this study, c.1600C>T
(p.R534C) and c.1703C>T (p.P568L), and three previ-
ously reported, c.641T>C (p.I214T), c.931C>T (p.R311*),
and c.1084C>T (p.R362C),11 have also been observed to
occur somatically in association with medulloblastoma,
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malignant melanoma, and esophageal squamous cell car-
cinoma (http://cancer.sanger.ac.uk/cosmic). Malignancy
has not been reported in the 31 patients included in this
study. However, pathway analysis for the highest 5% and
lowest 5% genes expressed in RNAseq data from dermal
fibroblasts obtained in one subject (Female 13) showed
enrichment in cell cycle control of chromosomal replica-
tion and double-strand break repair pathways (Table S2).
Future studies will elucidate whether individuals carrying
DDX3X variants are at risk for the development of malig-
nancies.21 In summary, we identified 31 unrelated patients
with causal variants in DDX3X and expanded the geno-
typic and phenotypic spectrum of DDX3X-related disor-
ders. The collective data suggest that DDX3X defects are a
frequent cause of syndromic ID in females, and the causal
variants are likely to be loss-of-function (ExAC database
showed pLI = 1.00 for DDX3X).22
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